C
Clara Mayo
Publications - 32
Citations - 3614
Clara Mayo is an academic researcher. The author has contributed to research in topics: Erlotinib & Lung cancer. The author has an hindex of 16, co-authored 32 publications receiving 3407 citations.
Papers
More filters
Journal ArticleDOI
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rafael Rosell,Teresa Moran,Cristina Queralt,Rut Porta,Felipe Cardenal,Carlos Camps,Margarita Majem,Guillermo Lopez-Vivanco,Dolores Isla,Mariano Provencio,A. Insa,Bartomeu Massuti,José Luis González-Larriba,Luis Paz-Ares,Isabel Bover,Rosario García-Campelo,Miguel Angel Moreno,Silvia Catot,Christian Rolfo,Noemi Reguart,Ramon Palmero,Jose Miguel Sanchez,Roman Bastus,Clara Mayo,Jordi Bertran-Alamillo,Miguel Angel Molina,Jose Javier Sanchez,Miquel Taron +27 more
TL;DR: Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment, and the association between the mutations and the outcome of erlotinib treatment is analyzed.
Journal ArticleDOI
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
R. Porta,J.M. Sánchez-Torres,Luis Paz-Ares,Bartomeu Massuti,Noemi Reguart,Clara Mayo,Pilar Lianes,Cristina Queralt,V. Guillem,Pablo Herrera Salinas,Silvia Catot,Dolores Isla,A. Pradas,Alfonso Gurpide,J. de Castro,E Polo,Teresa Puig,Miquel Taron,Ramon Colomer,Rafael Rosell +19 more
TL;DR: Erlotinib is active in brain metastases from NSCLC; this clinical benefit is related to the presence of activating mutations in exons 19 or 21 of the EGFR gene.
Journal ArticleDOI
Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations
Rafael Rosell,Miguel Angel Molina,Carlota Costa,Sara Simonetti,Anna Gimenez-Capitan,Jordi Bertran-Alamillo,Clara Mayo,Teresa Moran,Pedro Mendez,Felipe Cardenal,Dolores Isla,Mariano Provencio,Manuel Cobo,A. Insa,Rosario García-Campelo,Noemi Reguart,Margarita Majem,Santiago Viteri,Enric Carcereny,R. Porta,Bartomeu Massuti,Cristina Queralt,Itziar de Aguirre,Jose Miguel Sanchez,Maria Sanchez-Ronco,Jose Luis Mate,Aurelio Ariza,Susana Benlloch,Jose Javier Sanchez,Trever G. Bivona,Charles L. Sawyers,Miquel Taron +31 more
TL;DR: Low BRCA1 levels neutralized the negative effect of the T790M mutation and were associated with longer progression-free survival to erlotinib.
Journal ArticleDOI
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
Hernán Cortés-Funes,Carolina Gómez,Rafael Rosell,P. Valero,C. Garcia-Giron,Angela Velasco,Angel Izquierdo,Pilar Diz,Carlos Camps,D. Castellanos,Vicente Alberola,Felipe Cardenal,Jose-Luis Gonzalez-Larriba,J. M. Vieitez,I. Maeztu,Jose Javier Sanchez,Cristina Queralt,Clara Mayo,Pedro Mendez,Teresa Moran,Miquel Taron +20 more
TL;DR: EG FR TK mutational analysis is a novel predictive test for selecting lung adenocarcinoma patients for targeted therapy with EGFR TK inhibitors.
Journal ArticleDOI
KRAS Mutations in Lung Cancer
Niki Karachaliou,Clara Mayo,Carlota Costa,Ignacio Magri,Ana Giménez-Capitán,Miguel Angel Molina-Vila,Rafael Rosell +6 more
TL;DR: The clinical and pathologic characteristics of patients with NSCLC and with KRAS mutations are summarized, work that explores the predictive and prognostic influence ofKRAS mutations is described, and an overview of the "synthetic lethal" interactions and current approaches to targeting KRAS-mutant NSCLc is provided.